Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exit Interview: Abernethy Tells Why She’s Leaving FDA – But Staying On Her Own Path

Executive Summary

The FDA’s outgoing second-in-command, Amy Abernethy, is confident she’s leaving the agency in good hands but plans to continue to advocate for patients by focusing on areas such as trial design and use of real-world evidence. In this interview with Medtech Insight, Abernethy also talks about the work she put in to make sure there was a change in IT culture at the agency, among other topics.

You may also be interested in...



FDA’s Second-In-Command, Amy Abernethy, Departing Agency

US FDA principal deputy commissioner Amy Abernethy is set to leave the agency by the end of April. The surprise news comes in the midst of the Biden administration still figuring out who they want to lead the FDA.

FDA Will No Longer Regulate Certain Medical Software

The US agency published a final rule on 16 April that says eight medical software functions will no longer be classified as medical devices. The rule finalizes a statutory provision from the 21st Century Cures Act.

US FDA Nukes HHS Decision To Exempt Medical Gloves, Other Products From Regulatory Oversight

The agency has rescinded two previous notices issued by HHS, stating the FDA had no input on the notices before they were published and the rationale backing them was flawed.

Topics

UsernamePublicRestriction

Register

MT143745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel